$150.98
0.41% yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US05464T1043
Symbol
AXSM

Axsome Therapeutics, Inc. Stock price

$150.98
+16.30 12.10% 1M
+45.91 43.69% 6M
+66.37 78.44% YTD
+53.95 55.60% 1Y
+76.24 102.01% 3Y
+77.56 105.64% 5Y
+142.16 1,611.79% 10Y
+142.24 1,627.46% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.62 0.41%
ISIN
US05464T1043
Symbol
AXSM
Industry

New AI Insights on Axsome Therapeutics, Inc. Insights AI Insights on Axsome Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$7.6b
Enterprise Value
$7.5b
Net debt
positive
Cash
$325.3m
Shares outstanding
50.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.6 | 12.1
EV/Sales
13.3 | 11.9
EV/FCF
negative
P/B
103.2
Financial Health
Equity Ratio
10.0%
Return on Equity
-503.9%
ROCE
-69.5%
ROIC
-76.4%
Debt/Equity
2.6
Financials (TTM | estimate)
Revenue
$561.3m | $631.2m
EBITDA
$-208.4m | $-149.5m
EBIT
$-214.7m | $-169.1m
Net Income
$-229.5m | $-185.0m
Free Cash Flow
$-101.4m
Growth (TTM | estimate)
Revenue
65.8% | 63.7%
EBITDA
30.5% | 45.5%
EBIT
29.9% | 39.7%
Net Income
26.2% | 35.6%
Free Cash Flow
23.7%
Margin (TTM | estimate)
Gross
91.9%
EBITDA
-37.1% | -23.7%
EBIT
-38.3%
Net
-40.9% | -29.3%
Free Cash Flow
-18.1%
More
EPS
$-4.6
FCF per Share
$-2.0
Short interest
8.0%
Employees
683
Rev per Employee
$560.0k
Show more

Is Axsome Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Axsome Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Axsome Therapeutics, Inc. forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Axsome Therapeutics, Inc. forecast:

Buy
96%
Hold
4%

Financial data from Axsome Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
561 561
66% 66%
100%
- Direct Costs 46 46
51% 51%
8%
516 516
67% 67%
92%
- Selling and Administrative Expenses 517 517
34% 34%
92%
- Research and Development Expense 189 189
16% 16%
34%
-208 -208
31% 31%
-37%
- Depreciation and Amortization 6.38 6.38
0% 0%
1%
EBIT (Operating Income) EBIT -215 -215
30% 30%
-38%
Net Profit -230 -230
26% 26%
-41%

In millions USD.

Don't miss a Thing! We will send you all news about Axsome Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Axsome Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in December:
Positive
The Motley Fool
17 days ago
Viking Therapeutics is developing innovative medicines in a fast-growing area. Axsome Therapeutics is generating strong sales, and solid regulatory progress could improve things.
Neutral
GlobeNewsWire
21 days ago
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator
More Axsome Therapeutics, Inc. News

Company Profile

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Head office United States
CEO Herriott Tabuteau
Employees 683
Founded 2012
Website www.axsome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today